In patients with PV and ET treated with long-term ruxolitinib, JAK2 V617F complete molecular response or deep molecular response occurred in 18% of patients and was associated with lower risk of progression to secondary MF
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address Clinical Care Options, LLC 12001 Sunrise Valley Drive Suite 300 Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
Continue